We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Neoleukin Therapeutics, Inc's financial performance into perspective.
December 12, 2022
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
November 14, 2022
November 3, 2022
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting